GLP-1 Lawsuit Lawyer: Ozempic, Wegovy and Mounjaro Claims

Lawsuits allege that makers of GLP-1 receptor agonist drugs, used for diabetes and weight loss, failed to adequately warn about risks such as severe gastroparesis (stomach paralysis) and other complications. The drugs named include Ozempic, Wegovy and Rybelsus (Novo Nordisk) and Trulicity and Mounjaro (Eli Lilly). The makers deny the allegations.

• Gastroparesis (stomach paralysis)
• Ileus and intestinal obstruction
• NAION, a type of sudden vision loss (in a separate MDL)

People who took a GLP-1 drug and were diagnosed with a named condition may qualify. Every case depends on medical records and timing.

Gastrointestinal injury cases are consolidated as MDL No. 3094 before Judge Karen S. Marston in the U.S. District Court for the Eastern District of Pennsylvania. In September 2026 the court held a multi-day hearing on scientific evidence issues that apply across the cases. Vision-loss (NAION) cases are in a separate MDL, No. 3163, before the same judge. No global settlement has been announced. Source: U.S. District Court, E.D. Pa..

• Medical records showing the diagnosis
• Pharmacy or purchase records showing use of the product
• A timeline of when you used the product and when symptoms began

Kentucky product injury claims generally must be filed within one year of when the injury was discovered or reasonably should have been discovered. Rules vary by state and case, and court orders in these cases can set their own dates. Estimate dates with our statute of limitations calculator and talk with a lawyer.